JP2023528804A5 - - Google Patents

Info

Publication number
JP2023528804A5
JP2023528804A5 JP2022573211A JP2022573211A JP2023528804A5 JP 2023528804 A5 JP2023528804 A5 JP 2023528804A5 JP 2022573211 A JP2022573211 A JP 2022573211A JP 2022573211 A JP2022573211 A JP 2022573211A JP 2023528804 A5 JP2023528804 A5 JP 2023528804A5
Authority
JP
Japan
Prior art keywords
sars
cov
phorbol
pharmaceutical composition
tpa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528804A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/034494 external-priority patent/WO2021243007A2/en
Publication of JP2023528804A publication Critical patent/JP2023528804A/ja
Publication of JP2023528804A5 publication Critical patent/JP2023528804A5/ja
Pending legal-status Critical Current

Links

JP2022573211A 2020-05-28 2021-05-27 コロナウイルスが引き起こす急性呼吸窮迫症候群(ards)および炎症性障害を処置するための組成物および方法 Pending JP2023528804A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063031551P 2020-05-28 2020-05-28
US63/031,551 2020-05-28
PCT/US2021/034494 WO2021243007A2 (en) 2020-05-28 2021-05-27 Compositions and methods for treating acute respiratory distress syndrome (ards) and inflammatory disorders caused by coronaviruses and other respiratory pathogens or agents that mediate pulmonary injury, inflammation or acute respiratory distress, and related compositions and methods for treating and preventing human sars coronavirus infection, covid-19 disease and related symptoms

Publications (2)

Publication Number Publication Date
JP2023528804A JP2023528804A (ja) 2023-07-06
JP2023528804A5 true JP2023528804A5 (cg-RX-API-DMAC7.html) 2025-02-20

Family

ID=78722786

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573211A Pending JP2023528804A (ja) 2020-05-28 2021-05-27 コロナウイルスが引き起こす急性呼吸窮迫症候群(ards)および炎症性障害を処置するための組成物および方法

Country Status (12)

Country Link
US (3) US20230248684A1 (cg-RX-API-DMAC7.html)
EP (1) EP4304570A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023528804A (cg-RX-API-DMAC7.html)
KR (1) KR20230058014A (cg-RX-API-DMAC7.html)
CN (1) CN117015375A (cg-RX-API-DMAC7.html)
AU (1) AU2021281257A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024226A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180577A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003348A1 (cg-RX-API-DMAC7.html)
IL (1) IL298593B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022014958A (cg-RX-API-DMAC7.html)
WO (1) WO2021243007A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113444177A (zh) * 2020-03-27 2021-09-28 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
WO2021207497A1 (en) * 2020-04-08 2021-10-14 Arizona Board Of Regents On Behalf Of Arizona State University Covid-19 inflammatory cytokine storm treatment
US20230071393A1 (en) * 2020-04-16 2023-03-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Matrix bound vesicles (mbv) for treatment of acute respiratory distress syndrome
US11402391B2 (en) 2020-12-21 2022-08-02 Incelldx, Inc. Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist
CN115252760B (zh) * 2022-03-30 2024-05-31 厦门大学 一种广谱抗冠状病毒的制剂及其制备方法
WO2025029797A1 (en) * 2023-08-01 2025-02-06 Incelldx, Inc. Methods of assigning a covid pathological type and compositions for practicing the same, and methods of treating a subject for chronic covid-19
CN117304031A (zh) * 2023-09-05 2023-12-29 深圳大学 一种铁苋菜二萜类化合物、铁苋菜提取物及其在制备具有抗氧化和/或抗炎作用的产品中的应用
CN117414438B (zh) * 2023-11-01 2025-10-17 大连医科大学附属第一医院 一种靶向m1型巨噬细胞的多肽偶联药物及其应用
CN117919385B (zh) * 2024-02-05 2024-10-18 中国医学科学院医学实验动物研究所 IL-37在MERS-CoV感染疾病的治疗中的应用
CN121490288A (zh) * 2025-11-21 2026-02-10 中山大学附属第三医院 一种用于急性呼吸窘迫综合征的肺部交感神经局部光遗传激活系统及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP223198A0 (en) * 1998-03-06 1998-04-02 Fujisawa Pharmaceutical Co., Ltd. New use
US20030109486A1 (en) * 2001-10-31 2003-06-12 Eliezer Rapaport Methods and therapeutic compositions for utilization of adenosine 5'-triphosphate (ATP) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)
ES2464459T3 (es) * 2008-06-25 2014-06-02 H. Lundbeck A/S Modulación del sistema receptor Trpv:receptor de dominio Vps 10p para el tratamiento del dolor
WO2010036945A2 (en) * 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US20130203715A1 (en) * 2010-07-20 2013-08-08 Pulmatrix, Inc. Use of trp channel agonists to treat infections
KR101374760B1 (ko) * 2011-10-26 2014-03-17 한국생명공학연구원 포볼 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물
JP6977206B2 (ja) * 2016-03-31 2021-12-08 富山県 自然免疫を活性化する粘膜ワクチン用アジュバント
WO2019108456A1 (en) * 2017-12-01 2019-06-06 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same

Similar Documents

Publication Publication Date Title
Amirian et al. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
Diez-Porras et al. Guillain-Barré-Strohl syndrome and COVID-19: case report and literature review
US20220088403A1 (en) Methods And Compositions For Treating Coronavirus
EA035439B1 (ru) Амидное соединение и его применение в качестве средства для лечения и профилактики заболеваний, вызываемых рнк- и/или днк-содержащими вирусами, и сопутствующих заболеваний
RU2008145510A (ru) Композиции и способы диагностики и лечения астмы или других аллергических или воспалительных заболеваний
Pagliano et al. Is Hydroxychloroquine a possible postexposure prophylaxis drug to limit the transmission to healthcare workers exposed to coronavirus disease 2019?
WO2019033122A1 (en) TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
Zhang et al. Novel derivatives of brincidofovir and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl) adenine inhibit orthopoxviruses and human adenoviruses more potently than brincidofovir
JP2023535518A (ja) SARS-CoV-2及び他の病原性ウイルスの複製を遮断するためのWNT/β-カテニン経路阻害薬の使用
WO2021207155A1 (en) Airway epithelial alkaline therapy to treat viral respiratory infection
WO2021169984A1 (zh) 聚adp核糖聚合酶抑制剂在抗冠状病毒中的应用
Zhang et al. Modulating apoptosis as a novel therapeutic strategy against respiratory syncytial virus infection: insights from rotenone
US11433080B2 (en) Antiviral treatment
JP7346710B2 (ja) 新型コロナウイルス感染症の予防又は治療用医薬組成物
US12329727B2 (en) Use of salmeterol as an anti-coronaviral agent
WO2021255226A1 (en) Antiviral use of calixarenes
Kaushik et al. Glycolytic stress deteriorates 229E virulence to improve host defense response
CN117320748A (zh) Covid-19进入抑制剂对covid-19复制的遏制
EP4132518B1 (en) Dantrolene for use in methods of treating sars-cov-2 infections
Altay et al. Post-COVID-19 extensive maxillary actinomycotic osteonecrosis: A rare case report
CN115916189A (zh) 治疗严重急性呼吸综合征的方法
HK40083259B (en) Dantrolene for use in methods of treating sars-cov-2 infections
IT202300022647A1 (it) Uso di elysivir per il trattamento della malattia da coronavirus 2019 (covid-19)
HK40090314A (zh) 治疗严重急性呼吸综合征的方法
HK40104268A (en) Anti-viral agent